Login / Signup

Triple negative breast cancer: approved treatment options and their mechanisms of action.

Aditya MandapatiKiven Erique Lukong
Published in: Journal of cancer research and clinical oncology (2022)
The recent approval and use of therapies such as Trodelvy, olaparib and Keytruda has its roots in the development of an understanding of signaling pathways that drive tumour growth. In the future, the emergence of novel drug delivery methods may help increase the efficiency of these therapies whiel also reducing adverse side effects.
Keyphrases
  • drug delivery
  • drug administration
  • signaling pathway
  • current status
  • cancer therapy
  • epithelial mesenchymal transition
  • cell proliferation
  • drug release
  • adverse drug
  • induced apoptosis